ESR1 and breast carcinoma: Indeed, our results indicate that INPP4B-overexpressing ER+ breast cancers cells exhibit increased sensitivity towards LGK-974 or PRI-724 in combination with 4-OHT, suggesting that combining Wnt therapeutics with an endocrine therapy may be a potential strategy for this breast cancer subset.